Novo Nordisk reports that CagriSema outperformed tirzepatide with 12.4% weight loss versus 9.1% in a phase 3 trial in adults with type 2 diabetes.
|Articles|October 11, 2017
EMA Updates Guidelines on Excipients in Labeling
Author(s)BioPharm International Editors
Europe updates the guideline on excipients information in labeling and packaging.
Advertisement
On October 9, 2017, the European Medicines Agency (EMA) announced that the
The guideline was updated to take into consideration safety concerns not currently addressed in the existing annex, with specific attention to excipients that may affect children or pregnant women. Five new excipients are included, and 10 have been updated with new safety warnings.
Source:
Advertisement
Related to this article
AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.
SOTIO Biotech's LRRC15-targeted antibody-drug conjugate SOT106 now holds both Orphan Drug and Fast Track Designations in soft tissue sarcoma and osteosarcoma. The company expects to start first-in-human testing later in 2026.
The FDA has approved a label update for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION data, showing a 76% reduction in clinical worsening events when added to background therapy in adults diagnosed with pulmonary arterial hypertension within the past year.
FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.
Glycomine's GLM101, an investigational liposomal mannose-1-phosphate substrate replacement therapy, has received FDA Breakthrough Therapy designation for PMM2-CDG, a rare glycosylation disorder with no approved treatments.
New data show risk-based and centralized monitoring shifts effort across roles, sites, and timelines, reshaping how sponsors plan CRA capacity needs.
Fayuvi scored 23.5 points higher than untreated peers on cognitive testing, backing the first-ever approval for a Sanfilippo syndrome A gene therapy.
Advertisement
Advertisement